| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.2 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | JW-7-52-1 | GDSC1000 | pan-cancer | AAC | 0.068 | 0.2 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.068 | 0.2 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | 0.067 | 0.2 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.2 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.046 | 0.2 |